Lexicon Pharmaceuticals Inc. has announced that it will present data from a clinical study evaluating the impact of sotagliflozin on hypoglycemia in individuals with type 1 diabetes. The findings will be delivered as an oral presentation at the 85th Scientific Sessions of the American Diabetes Association $(ADA.AU)$ on Sunday, June 22, 2025. Additionally, Lexicon will present topline data from its PROGRESS Phase 2b study of pilavapadin (LX9211) for diabetic peripheral neuropathic pain. These presentations will take place during the congress held from June 20-23, 2025, at the McCormick Place Convention Center in Chicago, Illinois.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.